Simple blood test may reveal early if lung cancer therapy works
NCT ID NCT03926260
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 100 people with advanced non-small cell lung cancer to see if changes in tumor DNA in the blood (ctDNA) can predict how well treatment is working. Researchers took blood samples before treatment, at 3 weeks, and at 9 weeks. The goal was to see if a rise or fall in ctDNA levels matches tumor shrinkage or growth on scans. This is an observational pilot study, not a test of a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to quickly tell if lung cancer treatment is working, helping doctors adjust therapy earlier.
- What could go wrong
- This is a small, early pilot study (100 people) that only observes DNA changes—it does not test a new treatment. The findings may not apply to all patients or lead to a reliable test.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jaafar BENNOUNA
Nantes, 44000, France
-
Marie MARCQ
La Roche-sur-Yon, 85000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a new drug shrink Hard-to-Treat tumors?
- Breath test may reveal who benefits from lung cancer immunotherapy
- Targeted radiation and immunotherapy join forces against Hard-to-Treat lung cancer
- Triple-Drug cocktail targets tough lung cancer mutations